Navigation Links
Therapy slows onset and progression of Lou Gehrig's disease, study finds
Date:9/9/2013

at is to deliver the drug directly into the cerebrospinal fluid (CSF), which would reduce the amount of SOD1 suppression in cells outside the brain and reduce immune system exposure to AAV9elements that would add weight to an argument for studying the drug in humans.

Injections directly into CSF cannot be done easily in mice, so the team took the study a crucial step further by injecting AAV9-SOD1-shRNA into the CSF of healthy nonhuman primates. The results were just as the team hopedthe amount of gene expression dropped by as much as 90 percent in motor neurons and nearly 70 percent in astrocytes and no side effects were reported, laying the groundwork towards moving to human clinical trials.

"We have a vast amount of work to do to move this toward a clinical trial, but we're encouraged by the results to date and our team at Nationwide Children's and our outstanding collaborators are fully committed to making a difference in this disease," Dr. Kaspar said.

The findings could impact other studies underway in Dr. Kaspar's lab, including research on Spinal Muscular Atrophy, an often fatal genetic disease in infants and children that can cause profoundly weakened muscles in the arms and legs and respiratory failure.

"This research provides further proof of targeting motor neurons and glial cells throughout the entire spinal cord for treatment of Spinal Muscular Atrophy and other degenerative diseases of the brain and spinal cord, through a less invasive manner than direct injections," said Dr. Kaspar, who also is an associate professor of pediatrics and neurosciences at The Ohio State University College of Medicine.


'/>"/>

Contact: Gina Bericchia
Gina.Bericchia@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Physiotherapy in Singapore Clinic Urbanrehab Pte Ltd Announces the Opening of an Additional Location
2. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
3. ITN type 1 diabetes study identifies subset of patients with strong response to therapy
4. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
5. Study suggests way to fight therapy resistant leukemia by blocking DNA repair
6. An effective initial polytherapy for infantile spasms
7. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
8. Neuroblastoma: Autophagy protects from chemotherapy
9. Dendritic cell therapy improves kidney transplant survival, Pitt team says
10. No danger of cancer through gene therapy virus
11. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... Calif. Conservation biologist Michael Allen will give a ... 6 titled "In the Crosshairs: California,s Environment." The hour-long lecture ... Doors open at 6:15 p.m. Seating is open. In his ... Conservation Biology at UC Riverside, plans to discuss what the ...
... STILLWATER, Okla. , April 27 Southwest Bancorp, Inc. (Nasdaq: ... offering of 4,000,000 shares of common stock at a price to the public ... million .  The offering was increased from the previously announced offering size of ... April 29, 2010 . , , ...
... Recently the media has begun to criticize those ... financial reform legislation, or Consumer Financial Protection Agency (CFPA).  Although ... weeks, possibly due to the fact that our Senate is ... of the sweeping bill, we are still not seeing this ...
Cached Biology News:Public lecture at UC Riverside to highlight California's environment 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Pay1Day Asks, Who is Writing our Proposed Consumer Protection Bill? 2
(Date:3/27/2015)... NEW YORK , 27. März 2015 ... Vilcek Prize in Biomedical Science für seine ... wie Proteine zwischen Zellkompartimenten transportiert werden, sowie ... den Zellen zur Reaktion auf Stress nutzen, ... zusammenhängt. Dr. Walter ist Professor für Biochemie ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... 12 months ended December 31, 2014.  ... or ($0.05) per share, for the three months ended ...
(Date:3/26/2015)... Bruno, CA (PRWEB) March 26, 2015 ... (CRO), announced today several management and executive appointments ... of Chief Financial Officer (CFO) and member of the ... President of Business Operations, and Sue Dowden will assume ... Taricco, co-founder and current Chief Operations Officer (COO), has ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ - Beanstalk Capital Ltd. ... to the Company,s press,release dated October 16, 2007, ... announced that they had entered into an arm,s ... Agreement"),the Company and iCo would now like to ...
... Corporation plc,(NASDAQ: AMRN ) ("Amarin" or the "Company") ... will present at the Acumen,BioFin Rodman & Renshaw 9th ... Eastern time. The conference will be held on November,5 ... The presentation will be simultaneously webcast and a ...
... Provides Revised Timing on Interim Celgosivir Viral Kinetics Study ... ... Oct. 31 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer ... Renshaw 9th Annual,Healthcare Conference being held at the New York Palace Hotel ...
Cached Biology Technology:Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
... protein size markers are a mixture of ... to 100 kDa. The markers provide precise ... after staining with Coomassie blue. Because each ... sequence, the markers can also be detected ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... 220 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
... (3-ethylbenzthiazoline-6-sulfonic Acid) Clear to very pale ... H 2 O 2 in a citrate ... that is soluble, safe, convenient and has good ... intense blue-green color that can be measured at ...
Biology Products: